1 recruiting, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
Follow Genomic Instability: new trials by email Literature Review of Genomic Instability trials Research Report on Genomic Instability
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa, Placebo - Colorectal Cancer | Phase 3 | Recruiting | Exelixis | 600 | 2026-12-18 | 2026-11-12 |
| Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer Avelumab - POLE Exonuclease Mutant Colon Cancer, Microsatellite Instability | Phase 3 | Terminated | Royal Marsden NHS Foundation Trust | 30 | 2018-08-31 | 2022-10-07 |
Microsatellite Instability (2) · Colonic Neoplasms (1) · Colorectal Neoplasms (1)
Colonic Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Colorectal Neoplasms (1) · Rectal Diseases (1)
avelumab (1) · pembrolizumab (1)
Exelixis (1) · Royal Marsden NHS Foundation Trust (1)
United Kingdom (1) · United States (1)
Tony Dhillon, Bsc,FRCP, PhD (1)